Psilocybin Primes the Brain to Make Common Nerve Pain Drugs Work Far Better

Neuropathic pain is, in a sense, a glitch that refuses to self-correct. The original injury heals, or heals as much as it ever will, but the nervous system keeps insisting otherwise, flooding the brain with signals that serve no useful purpose except to make life miserable. Gabapentin is supposed to quiet that noise. For roughly half of patients it does, more or less. For the other half, it simply doesn’t work well enough, and the alternatives carry their own costs: opioids bring addiction risks, other anticonvulsants bring cognitive fog, and the underlying problem keeps grinding on. Now researchers at the University of Reading think they might have found a way to tip that balance, and it involves something you would not necessarily expect to find in a pain clinic.

A single dose of psilocybin, the compound responsible for the psychedelic effects of magic mushrooms, appears to restructure the brain’s pain-processing networks in ways that persist for weeks after the drug itself has cleared the body. And in doing so, it makes gabapentin dramatically more effective.

A Network Problem, Not Just a Chemical One

The study, published in Communications Biology, used mice in which chronic neuropathic pain had been induced by partial damage to the sciatic nerve, a well-established model that closely replicates the kind of persistent pain humans experience after surgery, trauma or diabetic nerve damage. When psilocybin was injected into these mice, pain relief appeared about two hours later and lasted, in some animals, for up to 30 days from a single dose. That duration is itself notable; most standard analgesics require daily dosing and tend to lose their grip as tolerance builds. Psilocybin, by contrast, seems to operate on the architecture of pain rather than just its symptoms.

The drug’s mechanism here involves the 5-HT2A serotonin receptor. When researchers pre-treated mice with volinanserin, a drug that blocks this receptor, the pain relief from psilocybin was substantially reduced. Which is at least a partial answer to the obvious question of how something primarily associated with altered consciousness ends up affecting something as specific as nerve pain. But only partial. Blocking 5-HT2A didn’t eliminate the effect entirely, suggesting other routes are probably involved, possibly including the release of BDNF, a protein that promotes the growth of new neural connections and has been implicated in psilocybin’s better-known antidepressant effects.

One detail from the experiments is worth sitting with for a moment. When the researchers gave psilocybin to mice 30 days before inducing the nerve injury, the drug did nothing. No protection, no preventive effect. This wasn’t a failure of the drug so much as a clue about how it works. Psilocybin, it seems, can only remodel networks that have already gone wrong. It doesn’t prevent the maladaptive changes that chronic pain causes in the brain; it reverses them once they’re established. A therapeutic tool, not a prophylactic.

The Gabapentin Experiment

The most striking finding came when the team gave gabapentin to mice that had received psilocybin weeks earlier. By that point, psilocybin’s own direct pain-relieving effect had faded entirely. The mice were no better off than the controls. Yet when gabapentin was administered 55 days after nerve injury (and roughly six weeks after the psilocybin dose), something quite different happened. In previously psilocybin-treated animals, gabapentin produced pain relief that lasted between two and four days. In mice that had only received saline instead of psilocybin, gabapentin’s effect was markedly weaker and shorter-lived.

“Millions of people live with nerve pain that their medication simply does not control well enough, and the medicines we do have can cause serious side effects or lead to addiction,” said Dr Maria Maiarú, the study’s senior author. “What is exciting here is that psilocybin does not just reduce pain on its own. It appears to reset the brain’s pain networks in a way that makes existing treatments significantly more effective. For patients who have run out of options, that could be genuinely transformative.”

The researchers describe this as psilocybin functioning as a “network primer”: not replacing gabapentin but preparing the brain’s pain circuitry to respond to it more fully. One plausible mechanism involves the anterior cingulate cortex, a region whose abnormal connectivity is closely linked to the chronification of pain, the process by which acute pain becomes permanent. Psilocybin has been shown elsewhere to normalise activity there. Another candidate is the structural plasticity the drug induces: previous research has documented that psilocybin causes rapid growth of dendritic spines (the tiny protrusions through which neurons form connections) in the prefrontal cortex, and these structural changes appear to persist for weeks. Exactly which of these mechanisms drives the enhanced gabapentin response, whether it’s cortical connectivity, spinal cord changes, BDNF release in the brainstem, or some combination, remains an open question.

Caveats Worth Noting

Mouse studies don’t translate to humans straightforwardly, and the pain research field has been burned before by promising preclinical results that didn’t survive clinical testing. A separate paper published earlier this year in Nature Communications reported no analgesic effect from psilocybin in several mouse pain models, which sits awkwardly alongside these results. The Reading team attributes the discrepancy partly to experimental design: measuring sustained effects over weeks, as they did, catches things that acute testing paradigms miss. Perhaps. The question will only really be settled in human trials.

The study did, however, confirm effects in both male and female mice, which matters more than it might sound. Pain research has historically been conducted almost exclusively in male animals, leaving genuine uncertainty about whether findings apply to women, who are disproportionately affected by many chronic pain conditions. Effects were confirmed in females here, though the duration differed slightly, with females showing about a week of relief from a single dose compared to up to a month in males. Whether that sex difference reflects something biologically real or is an artefact of the small numbers involved isn’t yet clear.

The researchers also found that repeated low-dose psilocybin, given weekly across three weeks, amplified the analgesic effect substantially compared to a single dose, suggesting there may be room to optimise the dosing strategy in future work. Co-administering psilocybin and gabapentin together also produced a stronger and more sustained response than either drug alone, which opens a second potential avenue: not just priming for later treatment, but acute combination use.

What none of this addresses yet is the psychedelic experience itself. The head-twitch response the researchers used to confirm that psilocybin had entered the central nervous system is the rodent proxy for psychedelic effects in humans. In a clinical setting, those effects would need managing, either therapeutically (as in the existing psilocybin-assisted psychotherapy model) or perhaps pharmacologically suppressed without losing the neuroplasticity benefits, which is a question several research groups are currently racing to answer. The idea that a single, supervised psilocybin session could make months of gabapentin more effective is appealing on paper; working out how to deliver that safely and equitably is another matter entirely.

For now, these results add to a growing body of preclinical evidence that psychedelics are doing something to pain networks that conventional analgesics simply cannot. Whether that translates to a usable treatment for the millions of people for whom current options are inadequate, remains to be seen. But the hypothesis that you might prime a broken system to accept repair, rather than endlessly patching it from the outside, is at least worth pursuing properly.

https://doi.org/10.1038/s42003-026-10065-7

Frequently Asked Questions

How does psilocybin reduce pain if it’s a psychedelic drug?

Psilocybin acts primarily on serotonin receptors, particularly 5-HT2A receptors, which are involved in regulating how the brain processes and interprets pain signals. Rather than simply blocking pain like a conventional analgesic, it appears to alter the connectivity patterns of brain networks that have become dysfunctional in chronic pain. Those network-level changes can persist for weeks after the drug itself has left the body, which is why a single dose produces effects that outlast its direct pharmacological action.

Why does psilocybin make gabapentin work better, even weeks later?

The short answer is that researchers don’t yet know precisely. The working hypothesis is that psilocybin induces lasting structural and functional changes in pain-processing circuits, including growth of new neural connections and normalised activity in brain regions like the anterior cingulate cortex. When gabapentin is then administered into this restructured neural environment, it may find more receptive circuitry to act on. This is what the authors call a “network primer” effect, though the exact mechanisms are still being investigated.

Could this work for people who already take gabapentin?

That’s the clinical question this research is pointing toward, but it hasn’t been tested in humans yet. The mouse experiments suggest that psilocybin could potentially help people who get limited benefit from gabapentin alone, which includes roughly 30 to 50 percent of neuropathic pain patients. Whether that holds in people, and how psilocybin would be administered alongside existing treatment plans, would need to be worked out in clinical trials.

Is this the same psilocybin used in depression research?

Yes. The compound is the same, and the mechanisms likely overlap: psilocybin’s ability to promote neuroplasticity and reset maladaptive brain connectivity is relevant to both conditions. Chronic pain and depression also frequently co-occur, and some researchers suspect psilocybin’s effects on both might share a common neural substrate. The drug used in the Reading study was actually supplied by Compass Pathways, a company that has been running psilocybin trials for treatment-resistant depression.

What are the main obstacles to using psilocybin for pain in practice?

Several. Psilocybin produces a significant psychedelic experience in humans, which requires careful clinical management, usually in a supervised therapeutic setting. It remains a controlled substance in most countries, which complicates both research and eventual prescribing. There are also open questions about dosing, how to combine it with existing treatments, and whether the effects seen in mice will translate to humans at all. The preclinical evidence is increasingly compelling, but clinical trials are the necessary next step.